Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

ONYX expands ONYX-015 clinical trials

March 4, 1997

Roche's Roferon-A receives EU approval

March 4, 1997

IGG's MMS-1 covered by patent

March 3, 1997

Immunotherapy cancer vaccine in phase II

Feb. 20, 1997

Encouraging results obtained for immunotoxin in Hodgkin's lymphoma

Feb. 17, 1997

Labeled SMART antibody shows promise for AML treatment

Feb. 17, 1997

Maxim's lead product approaches pivotal trials

Feb. 12, 1997

Genzyme Transgenics reports advances in transgenic production of MAbs

Feb. 11, 1997

Il Yang develops antitumor/immunostimulating proteoglycan

Feb. 7, 1997

AltaRex's lead product given orphan drug status

Jan. 17, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....